Postpartum Depression Drug Market Outlook, and Analysis 2018-2026
Increasing research activities for treatment of PPD is expected to propel growth of the Postpartum Depression Drug Market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is estimated to be completed in September 2020.
Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to be completed in June 2019.
Get Request a Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2258
Antidepressant drugs refusals by the U.S. Food and Drug Administration (U.S FDA) are expected to be a major restraint in growth of the postpartum depression drug market over the forecast period. For instance, in April 2018, the U.S FDA refused New Drug Application of Alkermes plc.’s drug candidate ALKS 5461 which is to be administered orally. The drug could be useful in treating depressive disorders, which cannot be treated by other standard drug therapies. This refusal was due to failures in action of this oral medication. On the basis of region, the global postpartum depression drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is estimated to hold dominant position in the global postpartum depression drug market during the forecast period, owing to increasing awareness of PPD. For instance, annually, May 2017 is celebrated as a National Maternal Depression Awareness Month recognizing the seriousness of depression during and after pregnancy in the U.S.
Download the PDF brochure @ www.coherentmarketinsights.com/insight/request-pdf/2258
Furthermore, Asia Pacific is expected to witness significant growth in the global postpartum depression drug market during the forecast period, owing to increasing prevalence of PDD in the region. For instance, According to World Health Organization (WHO) July 2018 report, 22% of mothers in India suffer from PPD, annually.
Postpartum Depression Drug Market– Taxonomy: By Drug Class, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants, Atypical Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), Others,. By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, By Region, North America, Europe, Asia Pacific, Latin America, Middle East, Africa,.
Key players operating in the global postpartum depression drug market include, Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd.
Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2258
About Coherent Market Insights:
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]